Search
Dasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39195] The approval of dasiglucagon marks the first glucagon analog approved for severe hypoglycemia treatment that does not require administration by a healthcare professional.[L39195] … It is characterized by neurological impairment, with manifestations like loss of consciousness and seizure.
Iodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast MediaUridine triacetate
go.drugbank.com/drugs/DB09144ApprovedIt is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself. … associated with fluorouracil and other antimetabolites, uridine triacetate is utilized for its ability to compete with 5-fluorouracil (5-FU) metabolites for incorporation into the genetic material of non-cancerous
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigationalSodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines
Olsalazine
go.drugbank.com/drugs/DB01250Approved[A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSLeucine
go.drugbank.com/drugs/DB00149ApprovedInvestigationalNutraceuticalAn essential branched-chain amino acid important for hemoglobin formation.
Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, Vamin NMecamylamine
go.drugbank.com/drugs/DB00657ApprovedInvestigationalMecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAlthough initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985.
Bupropion
go.drugbank.com/drugs/DB01156ApprovedInvestigational[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors ( … More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).